Focused On-demand Library for Keratin, type I cytoskeletal 9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P35527

UPID:

K1C9_HUMAN

Alternative names:

Cytokeratin-9; Keratin-9

Alternative UPACC:

P35527; O00109; Q0IJ47; Q14665

Background:

Keratin, type I cytoskeletal 9, also known as Cytokeratin-9 or Keratin-9, encoded by the gene with accession number P35527, plays a pivotal role in the structure and function of the epidermis. It is specifically involved in the assembly of keratin filaments, crucial for the integrity and mechanical resilience of the skin. This protein is predominantly expressed in the palmar and plantar epidermis, areas subjected to high mechanical stress.

Therapeutic significance:

Keratin-9 is directly implicated in Palmoplantar Keratoderma, a dermatological condition marked by the thickening of the skin on palms and soles. Understanding the role of Keratin-9 could open doors to potential therapeutic strategies for this and related skin disorders, offering hope for targeted treatments.